Fig 4. Changes of CD133 expression and cell cycle in VPA combined therapy at 72 hrs.

(A) Increased CD133+ cells in VPA combined therapy. Blue—isotype control (IgG2b-PE); red—CD133 expression detected by 239C3 (CD133/2) antibodies. (B) CD133+ cells were mainly located in the S and G₂/M phases, while CD133− were mainly present in the G₀/G₁ phases during treatment with cytostatics or in combination with VPA.